Table 2.

Demographic and clinical characteristics of HIV+ DLBCL cases by EBV status

EBV-negative (N = 48)EBV-positive (N = 22)P
Age, mean (SD), y47.9 (9.3)49.6 (9.5)0.49
Male gender, n (%)45 (93.8)19 (86.4)0.37
Race/ethnicity, n (%)
 White28 (58.3)13 (59.1)0.20
 Black9 (18.8)2 (9.1)
 Hispanic11 (22.9)5 (22.7)
 Asian/Pacific islander0 (0)2 (9.1)
Stage, n (%)
 I (localized)11 (22.9)5 (22.7)0.89
 II (regional)8 (16.7)4 (18.2)
 III (distant)25 (52.1)10 (45.5)
Extranodal involvement, n (%)
 Single site involvement12 (25.0)6 (27.3)
 ≥2 sites on the same side of the diaphragm9 (18.8)4 (18.2)
 Both sides of the diaphragm4 (8.3)4 (18.2)0.36
 Disseminated23 (47.9)7 (31.8)
Subtype, n (%)
 Centroblastic38 (79.2)13 (59.1)0.10
 Immunoblastic8 (16.7)5 (22.7)
 Plasmablastic2 (4.2)4 (18.2)
Germinal center phenotype, n (%)22 (47.8)5 (22.7)0.06
Detection of LMP1, n (%)NA8 (36.4)NA
Elevated serum LDH, n (%)25 (69.4)14 (73.7)0.74
ECOG performance status ≥2, n (%)9 (20)4 (20)1.00
Presence of B symptoms, n (%)11 (22.9)8 (36.4)0.35
IPI, n (%)
 0–1 (low-risk)11 (32.3)7 (41.2)0.91
 2 (low-intermediate risk)7 (20.6)4 (23.5)
 3 (high-intermediate risk)11 (32.3)4 (23.5)
 4–5 (high-risk)5 (14.7)2 (11.8)
Chemotherapy, n (%)42 (87.5)16 (72.7)0.17
 CHOP20 (47.6)8 (50.0)0.36
 RCHOP15 (35.7)4 (25.0)
 Other2 (4.8)3 (18.8)
HIV risk group, n (%)
 Heterosexual9 (18.8)6 (27.3)0.83
 Intravenous drug user1 (2.1)0 (0)
 Men who have sex with men22 (45.8)9 (40.9)
 Other/unknown16 (33.3)7 (31.8)
Known HIV duration, mean (SD), y6.2 (6.2)3.1 (4.0)0.06
Prior AIDS diagnosis, n (%)19 (39.6)12 (54.6)0.24
Prior use of cART, n (%)29 (60.4)16 (72.7)0.32
CD4 at diagnosis (cells/mm3), mean (SD)247.9 (169.0)128.4 (132.3)0.01
CD4 lowest KP recorded (cells/mm3), mean (SD)85.7 (72.2)43.8 (42.5)0.02

NOTE: Percentage may not add up to 100% due to missing values.

Abbreviations: CHOP, cyclophosphamide–Adriamycin–vincristine–prednisone; NA, not available; RCHOP, rituximab CHOP.